Navigation Links
FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
Date:4/4/2008

INDIANAPOLIS, April 4, 2008 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the European Commission has approved a new indication for FORSTEO(R) (teriparatide [rDNA origin] injection) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture. This approval follows the initial positive opinion issued in February by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA).

Teriparatide stimulates new bone formation by increasing the number and action of bone-building cells called osteoblasts. Teriparatide, originally authorized for marketing in 2003 for the treatment of osteoporosis in postmenopausal women at high risk for fracture, received an expanded indication for the treatment of osteoporosis in men at increased risk for fracture in 2007.

"Chronic glucocorticoid therapy is the most common cause of secondary osteoporosis, often leading to bone loss and an increased risk for fracture," said Gwen Krivi, Ph.D., vice president of Lilly Research Laboratories. "We are pleased with the European Commission's decision to approve teriparatide for this new use."

Glucocorticoid-induced osteoporosis, or GIOP, is bone loss associated with chronic use of glucocorticoid medications. These medications are often prescribed for inflammatory conditions, such as rheumatoid arthritis and obstructive pulmonary disease. Globally, an estimated one to three percent of adults over the age of 50 use glucocorticoids. (1)

"Up to 50 percent of individuals on chronic glucocorticoid therapy will develop bone loss leading to an osteoporotic fracture,"(2) said Dr. Steven Boonen, professor of medicine at the Leuven University Centre for Metabolic Bone Diseases in Belgium. "This new indication for teriparatide provides physicians and patients with a new treatment option that builds bone."

The submission package to support the safety and efficacy profile of teriparatide included new data from the "Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis" study, which was published in the November 15, 2007 issue of the New England Journal of Medicine. This head-to- head comparative study showed that in patients with glucocorticoid-induced osteoporosis, teriparatide significantly increased lumbar spine bone mineral density (BMD) from baseline (7.2 percent) compared to alendronate (3.4 percent) at 18 months of therapy.(3)

Information about Teriparatide

Teriparatide is the active fragment (1-34) of the human parathyroid hormone and acts to stimulate bone formation by directly affecting bone forming cells (osteoblasts), indirectly increasing the intestinal absorption of calcium and increasing the re-absorption of calcium and excretion of phosphate by the kidney. Teriparatide, marketed in the U.S. since 2002, was first approved in the E.U. in 2003 for the treatment of established osteoporosis in postmenopausal women who have an increased risk of fracture.

As part of drug testing, teriparatide was given to rats for a significant part of their lifetime. In these studies, teriparatide caused some rats to develop osteosarcoma, a bone cancer. Osteosarcoma in humans is a serious but very rare cancer. Osteosarcoma occurs in about four out of every million older adults each year. It is not known if humans treated with teriparatide also have a higher chance of getting osteosarcoma.

Teriparatide should be prescribed only to patients for whom the potential benefits are considered to outweigh the potential risk. The drug should not be prescribed for patients at increased baseline risk for osteosarcoma, including patients with Paget's disease of bone or unexplained elevations of alkaline phosphatase, children or growing adults, or those who have had prior external beam or implant radiation therapy involving the skeleton. Additionally, patients with bone metastases or a history of skeletal malignancies, and those with metabolic bone diseases other than osteoporosis, should not receive teriparatide. Patients with high levels of calcium in their blood should not receive teriparatide due to the possibility of increasing their blood levels of calcium.

In clinical trials, the most frequent treatment-related adverse events reported at the 20-microgram dose approved for marketing were mild, similar to placebo and generally did not require discontinuation of therapy. The most commonly reported adverse events in patients treated with teriparatide are nausea, pain in limb, headache and dizziness.

Teriparatide is supplied in a disposable pen device that can be used for up to 28 days to give once-daily self-administered injections. Teriparatide is available in a 20-microgram dose and should be taken for a period of up to 18 months. For full prescribing information, please visit http://www.lilly.co.uk.

About Osteoporosis

Osteoporosis is a debilitating disease that affects an estimated 75 million people in Europe, U.S. and Japan.(4) Osteoporosis, which means "porous bone," is a disease in which the density and quality of bone are reduced. As the bones become more porous and fragile, the risk of fracture is greatly increased. The loss of bone occurs "silently" and progressively and no symptoms are apparent until the first fracture occurs.(5)

The most common fractures associated with osteoporosis occur at the hip, spine and wrist. The incidence of these fractures, particularly at the hip and spine, increases with age in both women and men.(6) Vertebral fractures can result in serious consequences, including loss of height, intense back pain and deformity.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.co.uk.

Forward Looking Statement

This press release contains forward-looking statements about the safety and efficacy of teriparatide and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research, development, and commercialization. There is no guarantee that teriparatide for the treatment of osteoporosis, including with glucocorticoid-induced osteoporosis, will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

P-LLY

(1) Clin Rheumatol. 2007; 26: 144-153

(2) Endocrinol Metab Clin N Am. 2003; 32; 135-157.

(3) N Engl J Med. 2007; 357:2028-39.

(4) International Osteoporosis Foundation. "Facts and statistics about

osteoporosis and its impact." Available at http://www.iofbonehealth.org/facts-and- statistics.html#factsheet-category-22. Accessed on February 8, 2008.

(5) International Osteoporosis Foundation. "What is

osteoporosis?" Available at http://www.iofbonehealth.org/patients- public/about-osteoporosis/what-is-osteoporosis.html.

Accessed on February 8, 2008. (6) International Osteoporosis Foundation. "What is osteoporosis?"

Available at http://www.iofbonehealth.org/patients-public/about- osteoporosis/what-is-osteoporosis.html. Accessed on February 8, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars
2. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
3. Western Reserve Heart Care Receives ICANL Nuclear Medicine Accreditation
4. AIDS Activist Gregg Gonsalves Receives $100,000 Leadership Award
5. Emageon Receives Best in KLAS Cardiology PACS Award
6. London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. Alsius Corporation Receives Regulatory Approval in China and Mexico
9. North American Insurance Leaders, Inc. Receives an Estimate of Deep South 2007 Governing EBITDA
10. Human-Research Protection Program at Fred Hutchinson Cancer Research Center Receives National Accreditation
11. Cystic Fibrosis Foundation Receives Coveted 4-Star Rating for Sound Fiscal Management From Charity Navigator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Calibration, qualification, and the appropriate level ... maintaining GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled ... these requirements are explained. The challenge is to determine how to put ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology ... two biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance ... Bio Attendance uses biometric face recognition to enable users to check in and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the Self-Funding Success website has recently developed and published an informational resource that ... was created based on common inquiries the site’s team of third party administrator ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
(Date:3/27/2017)... 27, 2017 Summary This ... Eli Lilly and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... Columbia , March 27, 2017 LightIntegra ... has appointed William "Bill" Dubiel as President and Chief ... also elected to the Board of Directors of LightIntegra. ... the Executive Chairman of LightIntegra. "This ... next President and Chief Executive Officer. We,ve selected a ...
Breaking Medicine Technology: